Back to Treatments

Treatment

Ocrelizumab

1
Conditions
121
Trials
5,000
Participants
45%
Average Safety

Condition Evidence

Multiple sclerosis

121 trials · 5,000 participants

90% effectiveness · 45% safety
Ocrelizumab | DFDA